NEW YORK, Feb 15 – Incyte said Thursday it has signed a collaboration with Genicon Sciences, a privately-held San Diego company, to use Genicon’s protein detection methods to expand their diverse product line to include antibody arrays.
In the collaboration, Incyte will acquire rights to develop and commercialize Genicon’s Resonance Light Scattering technology, which can detect minute amounts of protein using light methods, in its antibody arrays. Incyte plans to introduce these antibody arrays later this year.
“We expect that Incyte's antibody arrays, treated with the RLS detection system, will provide faster and more cost-effective tools for measuring hundreds of proteins from thousands of biological samples,” said Incyte CEO Roy Whitfield in a statement. "These new products should reduce the time scientists will need to identify a gene that might be implicated in a disease or a gene that might affect the efficacy or safety of a drug.”
The RLS technology involves tiny light scattering particles that preferentially refract certain wavelengths of light. These particles work like chemiluminescent or fluorescent proteins used in chemical labels, but emit a signal that is up to a million times stronger than a fluorescent particle, Genicon said. Different light scattering particles can be designed to emit specific colors of light.
Incyte and Genicon said they believe this detection system, when incorporated in an array, could improve upon current radioactive, chemiluminescent, fluoresce, and other labeling systems and grab a large piece of the $600 labeling market for genomics and proteomics.
The companies did not disclose the financial terms of the agreement.